Bouchoucha M, Salles J P, Fallet M, Frileux P, Cugnenc P H, Barbier J P
Service d'Explorations Fonctionnelles, Hôpital-Laennec, Paris, France.
Biomed Pharmacother. 1992;46(4):161-5. doi: 10.1016/0753-3322(92)90024-2.
Pinaverium bromide is a specific calcium channel blocker used in the treatment of irritable bowel syndrome (IBS) for its spasmolytic activity. The aim of the present study was to evaluate the effect of orally administered pinaverium bromide on jejunal motility and total and segmental colonic transit time in control subjects. Gastrointestinal studies were performed in 10 healthy volunteers (30 +/- 3 years), before and after a treatment phase of 14 days (150 mg/d). Jejunal motility was measured by prolonged manometry (14 h) and colonic transit time by a multiple ingestion, single marker technique. No significant modification of phase III of the migrating motor complexes was demonstrated. On the contrary, a significant (p < 0.01) but weak decrease of the frequency of contraction was found. Unlike previous studies, no decrease of total or segmental colonic transit time was demonstrated.
溴丙胺太林是一种特定的钙通道阻滞剂，因其具有解痉活性而用于治疗肠易激综合征（IBS）。本研究的目的是评估口服溴丙胺太林对健康受试者空肠运动以及全结肠和节段性结肠转运时间的影响。对10名健康志愿者（30±3岁）在14天（150mg/天）的治疗阶段前后进行了胃肠道研究。通过延长测压法（14小时）测量空肠运动，通过多次摄入单一标记物技术测量结肠转运时间。未发现移行性运动复合波的第三相有明显改变。相反，发现收缩频率有显著（p<0.01）但微弱的降低。与先前的研究不同，未证明全结肠或节段性结肠转运时间有缩短。
